Predictive Technology Group Names Jay M. Moyes to Its Board of Directors
February 28 2019 - 9:00AM
Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the
use of data analytics for disease identification and subsequent
therapeutic intervention through precision therapeutic treatments,
announces that Jay M. Moyes has been named to the company’s Board
as an independent director, effective immediately. Moyes brings
more than 30 years of healthcare industry expertise in senior-level
financial positions and has significant governance experience from
Board memberships at publicly traded healthcare companies. His
appointment expands Predictive’s Board to five.
“We are delighted to attract a professional of Jay’s caliber as
we build out Predictive’s Board with proven leaders to support our
strategy of bringing proprietary genetic-based diagnostics and
therapeutics to market,” said Bradley C. Robinson, CEO of
Predictive Technology Group. “Jay’s extensive financial background
in companies spanning from development-stage to commercial
operations in diagnostics, genetics and therapeutics makes him
ideally suited for this role. His wealth of governance experience
from many years on multiple healthcare Boards will be particularly
valuable, and we are excited to welcome Jay to our Board.”
“I’m delighted to join this company on the cutting-edge of
precision medicine,” said Moyes. “Predictive’s approach to
using proprietary, extensive genetic data analytics to bring novel
diagnostics and therapeutics to underserved markets in women’s
health and spinal disease positions it to make important
contributions to improving health care. I look forward to working
toward achieving the company’s goals.”
Moyes previously served as Chief Financial Officer and Director
of the publicly traded biomaterials company Amedica Corporation,
now SINTX Technologies, where he managed the company’s IPO and
listing on NASDAQ, and as Chief Financial Officer at publicly
traded CareDx, a molecular diagnostics company where he introduced
a strategy to reach profitability. Prior to that he held senior
finance positions including Chief Financial Officer during his
14-year tenure at publicly traded Myriad Genetics. In
addition to overseeing all financial aspects at Myriad as the
company transitioned from 10 to more than 900 employees, he was
instrumental in raising more than $500 million in public and
private financings. He previously was Vice President of Finance and
Chief Financial Officer of Genmark, a private genetics company.
Moyes began his career in public accounting at KPMG.
Moyes serves on the Boards of Directors of Achieve Life Sciences
(NASDAQ: ACHV), BioCardia (OTC/QB: BCDA) and Puma Biotechnologies
(NYSE: PBYI). In addition to Amedica, he previously was a director
and Chairman of the Audit Committee of both Osiris Therapeutics
(NASDAQ: OSIR) and Integrated Diagnostics. He also served as a
member of the Board of Trustees of the Utah Life Science
Association. Moyes holds a BA in economics from Weber State
University and an MBA from the University of Utah.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care
through predictive data analytics, novel gene-based diagnostics and
companion therapeutics through its subsidiaries Predictive
Therapeutics, Predictive Biotech, Predictive Diagnostics and
Predictive Laboratories. These subsidiaries are focused on
endometriosis, scoliosis, degenerative disc disease and human cell
and tissue products. The subsidiaries use genetic and other
information as cornerstones in the development of new diagnostics
that assess a person’s risk of illness and therapeutic products
designed to identify, prevent and treat diseases more
effectively. Additional information is available at
Predtechgroup.com; Predrx.com and Predictivebiotech.com.
Forward-Looking StatementsTo the extent any
statements made in this release contain information that is not
historical, these statements are essentially forward-looking and
are subject to risks and uncertainties, including the difficulty of
predicting FDA approvals, acceptance and demand for human cell and
tissue products and other pharmaceutical products, the impact of
competitive products and pricing, new product development and
launch, reliance on key strategic alliances, availability of raw
materials, availability of additional intellectual property rights,
availability of future financing sources, the regulatory
environment, and other risks the Company may identify from time to
time in the future.
Contact:
InvestorsLHA Investor RelationsJody Cain jcain@lhai.comKevin Mc
Cabe kmccabe@lhai.com310-691-7100
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Apr 2023 to Apr 2024